These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2115904)

  • 21. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global review of multidrug therapy (MDT) in leprosy.
    Noordeen SK; Lopez Bravo L; Daumerie D
    World Health Stat Q; 1991; 44(1):2-15. PubMed ID: 2068821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy.
    Balakrishnan S; Kumar A; Rao BR; Patro TP
    Indian J Lepr; 1986; 58(4):555-9. PubMed ID: 3572097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disabilities in multibacillary leprosy patients: before, during and after multidrug therapy.
    Sharma P; Kar HK; Beena KR; Kaur H; Narayan R
    Indian J Lepr; 1996; 68(2):127-36. PubMed ID: 8835580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multidrug therapy in multibacillary leprosy; experience in an urban leprosy center.
    Ramesh V; Misra RS; Saxena U
    Int J Lepr Other Mycobact Dis; 1992 Mar; 60(1):13-7. PubMed ID: 1602189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hansen's disease in Portugal: multibacillary patients treated between 1988 and 2003.
    Medeiros S; Catorze MG; Vieira MR
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):29-35. PubMed ID: 18713227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A computer simulation of the effect of multidrug therapy on the incidence of leprosy.
    Lechat MF; Misson CB; Vanderveken M; Vellut CM; Declercq EE
    Ann Soc Belg Med Trop; 1987 Mar; 67(1):59-65. PubMed ID: 3632078
    [No Abstract]   [Full Text] [Related]  

  • 29. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 30. Multidrug therapy--the pathway for global leprosy elimination.
    al-Qubati Y; al-Kubati AS
    Indian J Lepr; 2000; 72(4):477-90. PubMed ID: 11212482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deformity incidence in leprosy patients treated with multidrug therapy.
    Rao PS; Subramanian M; Subramanian G
    Indian J Lepr; 1994; 66(4):449-54. PubMed ID: 7714354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of multidrug therapy on leprosy in Baroda district (Gujarat).
    Chopra NK; Agarwal JS; Pandya PG
    Indian J Lepr; 1989 Apr; 61(2):179-89. PubMed ID: 2746026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):259-69. PubMed ID: 10575405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SIMLEP: a simulation model for leprosy transmission and control.
    Meima A; Gupte MD; van Oortmarssen GJ; Habbema JD
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):215-36. PubMed ID: 10575401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
    Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of MDT on incidence rates of leprosy among household contacts. Part 1. Baseline data.
    Sundar Rao PS; Jesudasan K; Mani K; Christian M
    Int J Lepr Other Mycobact Dis; 1989 Sep; 57(3):647-51. PubMed ID: 2778370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapses in paucibacillary leprosy after MDT--a clinical study.
    Grugni A; Nadkarni NJ; Kini MS; Mehta VR
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of relapse in leprosy after fixed-duration multidrug therapy.
    Li HY; Hu LF; Huang WB; Liu GC; Yuan LC; Jin Z; Li X; Li JL; Yang ZM
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):238-45. PubMed ID: 9251597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in new case-detection leprosy in Bihar, India.
    Vijayakumaran P; Prasad B; Krishnamurthy P
    Indian J Lepr; 2006; 78(2):145-51. PubMed ID: 16927849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of MDT in multibacillary leprosy.
    Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
    Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.